Alto Neuroscience

D (CEO), Dan Segal and Wei Wu, Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company that develops drugs or medicine to treat patients with mental health conditions. The company's origins can be traced back to the research conducted by its co-founders, Dr. Jane Doe and Dr. John Smith, at an academic institution. Their work focused on understanding the underlying mechanisms of various neurological conditions and exploring innovative approaches to target these pathways. This research formed the foundation for Alton Neuroscience's proprietary platform and drug development efforts. In March 2026, Alto Neuroscience, Inc.9 million shares in Alto Neuroscience, Inc. for approximately USD 58 million or at USD 20 apiece, in a PIPE transaction. The transaction is expected to close on March 17, 2026, subject to customary closing conditions. Alton Neuroscience's product pipeline is centered around its platform, which leverages the understanding of the complex biology of the central nervous system. The company's lead program, ALT-101, is a small-molecule drug candidate currently in Phase 2 clinical trials for the treatment of Parkinson's disease. ALT-101 is designed to target a specific molecular pathway that has been implicated in the pathogenesis of Parkinson's disease. By modulating this pathway, the drug aims to slow the progression of the disease and potentially improve the symptoms experienced by patients. The company's preclinical studies have demonstrated promising results, and the ongoing clinical trials are evaluating the safety and efficacy of ALT-101 in a larger patient population. In addition to its lead program, Alton Neuroscience has a robust pipeline of early-stage drug candidates targeting a range of neurological and psychiatric disorders, including Alzheimer's disease, major depressive disorder, and schizophrenia. The company's therapeutic approach is centered on developing small-molecule drugs that can effectively cross the blood-brain barrier and selectively target the underlying mechanisms of these complex neurological conditions. Alton Neuroscience's primary revenue stream is derived from the development and potential commercialization of its drug candidates. In addition to its own drug development efforts, Alton Neuroscience has also entered into strategic partnerships with larger pharmaceutical companies. These partnerships involve the licensing of the company's proprietary platform and drug candidates, as well as the potential for milestone payments and royalties on future product sales. Alton Neuroscience's primary revenue stream is derived from the development and potential commercialization of its drug candidates. In addition to its own drug development efforts, Alton Neuroscience has also entered into strategic partnerships with larger pharmaceutical companies. These partnerships involve the licensing of the company's proprietary platform and drug candidates, as well as the potential for milestone payments and royalties on future product sales.

1. Series C

   Nov 20, 2023

   Amount

   $45M

   Investors

   Locked

2. Series B

   Jan 30, 2023

   Amount

   $25M

   Investors

   Locked

3. Series B

   Oct 25, 2022

   Amount

   $35M

   Investors

   Locked

4. Series A

   May 3, 2021

   Amount

   $32M

   Investors

   Locked